Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe
Chimeric antigen receptor T cell therapies are revolutionizing the clinical practice of hematological tumors, whereas minimal progresses have been achieved in the solid tumor arena. Multiple reasons have been ascribed to this slower pace: The higher heterogeneity, the hurdles of defining reliable tu...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/21/5351 |
| _version_ | 1797468841655140352 |
|---|---|
| author | Luciano Castiello Laura Santodonato Mariarosaria Napolitano Davide Carlei Enrica Montefiore Domenica Maria Monque Giuseppina D’Agostino Eleonora Aricò |
| author_facet | Luciano Castiello Laura Santodonato Mariarosaria Napolitano Davide Carlei Enrica Montefiore Domenica Maria Monque Giuseppina D’Agostino Eleonora Aricò |
| author_sort | Luciano Castiello |
| collection | DOAJ |
| description | Chimeric antigen receptor T cell therapies are revolutionizing the clinical practice of hematological tumors, whereas minimal progresses have been achieved in the solid tumor arena. Multiple reasons have been ascribed to this slower pace: The higher heterogeneity, the hurdles of defining reliable tumor antigens to target, and the broad repertoire of immune escape strategies developed by solid tumors are considered among the major ones. Currently, several CAR therapies are being investigated in preclinical and early clinical trials against solid tumors differing in the type of construct, the cells that are engineered, and the additional signals included with the CAR constructs to overcome solid tumor barriers. Additionally, novel approaches in development aim at overcoming some of the limitations that emerged with the approved therapies, such as large-scale manufacturing, duration of manufacturing, and logistical issues. In this review, we analyze the advantages and challenges of the different approaches under development, balancing the scientific evidences supporting specific choices with the manufacturing and regulatory issues that are essential for their further clinical development. |
| first_indexed | 2024-03-09T19:12:02Z |
| format | Article |
| id | doaj.art-29d82d968bf94d05aafae0e06b4c8169 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T19:12:02Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-29d82d968bf94d05aafae0e06b4c81692023-11-24T04:03:04ZengMDPI AGCancers2072-66942022-10-011421535110.3390/cancers14215351Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect RecipeLuciano Castiello0Laura Santodonato1Mariarosaria Napolitano2Davide Carlei3Enrica Montefiore4Domenica Maria Monque5Giuseppina D’Agostino6Eleonora Aricò7Cell Factory FaBioCell, Core Facilities, Italian National Institute of Health, 00161 Rome, ItalyCell Factory FaBioCell, Core Facilities, Italian National Institute of Health, 00161 Rome, ItalyResearch Coordination and Support Service, Italian National Institute of Health, 00161 Rome, ItalyCell Factory FaBioCell, Core Facilities, Italian National Institute of Health, 00161 Rome, ItalyCell Factory FaBioCell, Core Facilities, Italian National Institute of Health, 00161 Rome, ItalyCell Factory FaBioCell, Core Facilities, Italian National Institute of Health, 00161 Rome, ItalyCell Factory FaBioCell, Core Facilities, Italian National Institute of Health, 00161 Rome, ItalyCell Factory FaBioCell, Core Facilities, Italian National Institute of Health, 00161 Rome, ItalyChimeric antigen receptor T cell therapies are revolutionizing the clinical practice of hematological tumors, whereas minimal progresses have been achieved in the solid tumor arena. Multiple reasons have been ascribed to this slower pace: The higher heterogeneity, the hurdles of defining reliable tumor antigens to target, and the broad repertoire of immune escape strategies developed by solid tumors are considered among the major ones. Currently, several CAR therapies are being investigated in preclinical and early clinical trials against solid tumors differing in the type of construct, the cells that are engineered, and the additional signals included with the CAR constructs to overcome solid tumor barriers. Additionally, novel approaches in development aim at overcoming some of the limitations that emerged with the approved therapies, such as large-scale manufacturing, duration of manufacturing, and logistical issues. In this review, we analyze the advantages and challenges of the different approaches under development, balancing the scientific evidences supporting specific choices with the manufacturing and regulatory issues that are essential for their further clinical development.https://www.mdpi.com/2072-6694/14/21/5351immunotherapychimeric antigen receptorsolid tumorgene therapies |
| spellingShingle | Luciano Castiello Laura Santodonato Mariarosaria Napolitano Davide Carlei Enrica Montefiore Domenica Maria Monque Giuseppina D’Agostino Eleonora Aricò Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe Cancers immunotherapy chimeric antigen receptor solid tumor gene therapies |
| title | Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe |
| title_full | Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe |
| title_fullStr | Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe |
| title_full_unstemmed | Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe |
| title_short | Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe |
| title_sort | chimeric antigen receptor immunotherapy for solid tumors choosing the right ingredients for the perfect recipe |
| topic | immunotherapy chimeric antigen receptor solid tumor gene therapies |
| url | https://www.mdpi.com/2072-6694/14/21/5351 |
| work_keys_str_mv | AT lucianocastiello chimericantigenreceptorimmunotherapyforsolidtumorschoosingtherightingredientsfortheperfectrecipe AT laurasantodonato chimericantigenreceptorimmunotherapyforsolidtumorschoosingtherightingredientsfortheperfectrecipe AT mariarosarianapolitano chimericantigenreceptorimmunotherapyforsolidtumorschoosingtherightingredientsfortheperfectrecipe AT davidecarlei chimericantigenreceptorimmunotherapyforsolidtumorschoosingtherightingredientsfortheperfectrecipe AT enricamontefiore chimericantigenreceptorimmunotherapyforsolidtumorschoosingtherightingredientsfortheperfectrecipe AT domenicamariamonque chimericantigenreceptorimmunotherapyforsolidtumorschoosingtherightingredientsfortheperfectrecipe AT giuseppinadagostino chimericantigenreceptorimmunotherapyforsolidtumorschoosingtherightingredientsfortheperfectrecipe AT eleonoraarico chimericantigenreceptorimmunotherapyforsolidtumorschoosingtherightingredientsfortheperfectrecipe |